(12) International Application Status Report

Received at International Bureau: 09 December 2019 (09.12.2019)

Information valid as of: 12 May 2020 (12.05.2020)

Report generated on: 24 September 2020 (24.09.2020)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2020/11286004 June 2020 (04.06.2020) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/US2019/06338326 November 2019 (26.11.2019) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
62/773,767 (US)30 November 2018 (30.11.2018) Priority document received (in compliance with PCT Rule 17.1)
62/904,283 (US)23 September 2019 (23.09.2019) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
C07K 14/705 (2006.01); C12N 5/00 (2006.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01)

(71) Applicant(s):
INTIMA BIOSCIENCE, INC. [US/US]; 3 Columbus Circle New York, New York 10019 (US) (for all designated states)

(72) Inventor(s):
HENLEY, Thomas; 3 Columbus Circle New York, New York 10019 (US)
CHOUDHRY, Modassir; 3 Columbus Circle New York, New York 10019 (US)
VINEY, Lydia; 3 Columbus Circle New York, New York 10019 (US)

(74) Agent(s):
GRANT, Angela M.; Wilson Sonsini Goodrich & Rosati 650 Page Mill Road Palo Alto, California 94304 (US)

(54) Title (EN): METHODS OF IDENTIFYING IMMUNOMODULATORY GENES
(54) Title (FR): PROCÉDÉS D'IDENTIFICATION DE GÈNES IMMUNO-MODULATEURS

(57) Abstract:
(EN): Disclosed herein are methods for identifying immunomodulatory genes. In some embodiments, the method comprises of screening a candidate gene comprising: a) expressing an exogenous cellular receptor, or a functional portion thereof, in a plurality of immune cells; b) introducing into said plurality of immune cells: i. a guiding polynucleic acid, or a nucleic acid encoding said guiding polynucleic acid, wherein said guiding polynucleic acid targets said candidate gene; and ii. an exogenous nuclease, or a nucleic acid encoding said exogenous nuclease; thereby generating a plurality of engineered immune cells comprising a genomic disruption in said candidate gene; c) contacting said plurality of engineered immune cells with a plurality of cells expressing a cognate antigen of said exogenous cellular receptor or a functional portion thereof, thereby performing an in vitro assay; and d) determining a readout of said in vitro assay.
(FR): L'invention concerne des procédés d'identification de gènes immuno-modulateurs. Dans certains modes de réalisation, le procédé comprend le criblage d'un gène candidat comprenant : a) l'expression d'un récepteur cellulaire exogène, ou d'une portion fonctionnelle de celui-ci, dans une pluralité de cellules immunitaires ; b) l'introduction dans ladite pluralité de cellules immunitaires : i. d'un acide polynucléique de guidage ou d'un acide nucléique qui code ledit acide polynucléique de guidage, ledit acide polynucléique de guidage ciblant ledit gène candidat ; et ii. d'une nucléase exogène ou d'un acide nucléique qui code ladite nucléase exogène ; ce qui permet de générer une pluralité de cellules immunitaires modifiées comprenant une interruption génomique dans ledit gène candidat ; c) la mise en contact de ladite pluralité de cellules immunitaires modifiées avec une pluralité de cellules exprimant un antigène parent dudit récepteur cellulaire exogène ou d'une portion fonctionnelle de celui-ci, réalisant ainsi un dosage in vitro ; et d) la détermination d'une lecture dudit dosage in vitro.

International search report:
Received at International Bureau: 05 March 2020 (05.03.2020) [US]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:
Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate
Declaration made as applicant's entitlement, as at the international filing date, to claim the priority of the earlier application, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii))